NASDAQ:MBRX opened at $1.24 on Tuesday. The business has a fifty day simple moving average of $1.63 and a two-hundred day simple moving average of $1.79. Moleculin Biotech has a 1 year low of $1.02 and a 1 year high of $3.99. The company has a market capitalization of $35.44 million, a P/E ratio of -2.10 and a beta of 1.84.
Moleculin Biotech (NASDAQ:MBRX – Get Rating) last released its earnings results on Wednesday, May 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03). Analysts forecast that Moleculin Biotech will post -0.94 EPS for the current year.
Moleculin Biotech Company Profile (Get Rating)
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
- Get a free copy of the StockNews.com research report on Moleculin Biotech (MBRX)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.